Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Long-Term Safety of Baricitinib for RA

Michele B. Kaufman, PharmD, BCGP  |  December 14, 2020

Baricitinib appears to be a safe long-term treatment for RA patients, according to a recent analysis of patients with drug exposure up to eight years.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2020baricitinibJAK inhibitorRheumatoid Arthritis (RA)

The End of the Beginning: COVID-19 Vaccines & Other Conundrums

Philip Seo, MD, MHS  |  December 9, 2020

“It’s like winning Powerball.” For months, there has been a steady trickle of questions from my patients, asking for my opinion about the new vaccines being developed to prevent COVID-19. More to the point, they want to know if they should be vaccinated. After some fits and starts, I finally struck upon a pat answer…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:COVID-19

Medicare’s Most Favored Nation Is My Least Favorite Notion!

Angus B. Worthing, MD  |  December 8, 2020

In case you missed it, on Nov. 20, the  Centers for Medicare & Medicaid Services (CMS), a department within the U.S. Department of Health and Human Services, announced that it will overhaul the payment system for Medicare Part B (i.e., infusion) drugs on Jan. 1, 2021. The plan is called the Most Favored Nation (MFN)…

Filed under:Legislation & AdvocacyOpinionProfessional TopicsSpeak Out Rheum Tagged with:MedicareMost Favored Nation

ACR Convergence graphic

10 Clinical Insights from Rheumatology Top Secrets & Pearls

Vanessa Caceres  |  December 7, 2020

In this ACR Convergence session, Jason R. Kolfenbach, MD, & John H. Stone, MD, MPH, shared clinical insights about rheumatic diseases.

Filed under:ACR ConvergenceConditionsMeeting ReportsVasculitis Tagged with:ACR Convergence 2020DiagnosisGCAgiant cell arteritis (GCA)Inflammatory Eye DiseaseVasculitis

A Year to Remember: Dr. Jinoos Yazdany Presents the 2020 Clinical Research Review

Jason Liebowitz, MD, FACR  |  December 7, 2020

During ACR Convergence 2020, Jinoos Yazdany, MD, MPH, discussed innovative research into a potential treatment for lupus, medication tapering & more. These findings may influence the treatment of rheumatic disease in the future.

Filed under:ACR ConvergenceConditionsMeeting ReportsResearch Rheum Tagged with:ACR Convergence 2020anifrolumabaxial spondyloarthritis (SpA)Clinical researchCOVID-19GlucocorticoidsLupusrituximabVasculitis

Patients Demonstrated Good Medication Adherence While Taking Biosimilar Treatment

Michele B. Kaufman, PharmD, BCGP  |  December 7, 2020

Researchers found half of patients taking the biosimilar infliximab-dyyb (Inflectra) remained highly adherent to medication use after 12 months.

Filed under:ACR ConvergenceBiologics/DMARDsDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2020adherenceINFLECTRA (infliximab-dyyb)infliximab-dyyb

The Pandemic in Rural America: A Q&A with Chris Morris, MD

Kimberly Retzlaff  |  December 7, 2020

In rural America, where rheumatology offices are fewer and farther between, the expansion of telemedicine has been a boon during the COVID-19 pandemic. However, lab closures and reduced hospital services have made monitoring patients’ medications more challenging.

Filed under:Professional Topics Tagged with:COVID-19ruralrural areastelemedicine

COVID-19 Risks & Treatment for Patients with Rheumatic Disease

Thomas R. Collins  |  December 4, 2020

The Global Rheumatology Alliance is an important tool for assessing COVID-19 risk, & the ACR COVID-19 Task Force provides treatment guidance to rheumatology practitioners.

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2020COVID-19COVID-19 Global Rheumatology AllianceGlobal Rheumatology Alliance

Effects of Warfarin on Risk of Hip & Knee Replacement in OA Patients

Michele B. Kaufman, PharmD, BCGP  |  December 4, 2020

The use of warfarin may increase the risk of knee or hip replacement in patients with osteoarthritis (OA), according to research presented during ACR Convergence 2020.

Filed under:ACR ConvergenceDrug UpdatesMeeting Reports Tagged with:ACR Convergence 2020hipkneeOsteoarthritiswarfarin

Emergency Use Approved for Baricitinib with Remdesivir Combination Therapy for SARS-CoV-2

Michele B. Kaufman, PharmD, BCGP  |  December 3, 2020

The FDA issued an emergency use authorization for the use of baricitinib combined with remdesivir to treat patients hospitalized with COVID-19.

Filed under:Drug Updates Tagged with:baricitinibCOVID-19FDAremdesivirU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • …
  • 82
  • 83
  • 84
  • 85
  • 86
  • …
  • 326
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences